Millions of People Could Live Thanks to New Access to Tuberculosis Medication

Johnson & Johnson announced on Friday that the company will not enforce patents for the lifesaving tuberculosis treatment bedaquiline in 134 low- and middle-income countries globally. Bedaquiline, which was approved in 2012, is an essential part of treatment for multidrug-resistant... #press

https://www.motherjones.com/politics/2023/10/johnson-johnson-tuberculosis-drug-resistance-patent/?utm_source=press.coop